Form 4: Amphastar Pharmaceuticals Director Sells Shares Under Pre-Arranged Trading Plan

A director at Amphastar Pharmaceuticals, Floyd F. Petersen, sold 500 shares of common stock for approximately $23.47 per share as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Floyd F. Petersen, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), sold 500 shares of the company's common stock.
• The transaction occurred on July 2, 2025, at a weighted average price of $23.4679 per share.
• The shares were sold in multiple transactions with prices ranging from $23.335 to $23.625.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Petersen on November 26, 2024.
• Following this transaction, Mr. Petersen directly beneficially owns 77,531 shares of Amphastar Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about its timing or motivation, making it a routine disclosure.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to immediate market conditions or non-public information, which can mitigate negative investor sentiment often associated with insider sales.

Negatives

• A director's sale of shares, even if pre-planned, reduces their direct ownership stake in the company, which some investors might interpret as a slight reduction in alignment with shareholder interests.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the pharmaceutical sector.

Related Party Transactions

• The sale of 500 shares of common stock by Director Floyd F. Petersen is a related party transaction.

Stakeholder Impact

• Shareholders: The sale by a director, even under a 10b5-1 plan, slightly reduces insider ownership, which could be interpreted by some as a minor decrease in management's direct financial alignment with shareholders. However, the pre-planned nature typically lessens any negative impact.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, SEC Form 4, Insider Trading, Director Share Sale, Rule 10b5-1 Plan, Common Stock, Pharmaceuticals